Relay Therapeutics, Inc.
RLAY
$12.78
-$0.44-3.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 10.68M | 15.36M | 8.36M | 8.36M | 7.68M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.68M | 15.36M | 8.36M | 8.36M | 7.68M |
| Cost of Revenue | 256.26M | 259.51M | 267.60M | 276.33M | 306.85M |
| Gross Profit | -245.58M | -244.15M | -259.24M | -267.97M | -299.17M |
| SG&A Expenses | 50.88M | 58.59M | 65.55M | 72.79M | 79.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 307.14M | 318.09M | 333.14M | 349.12M | 386.03M |
| Operating Income | -296.46M | -302.74M | -324.79M | -340.76M | -378.35M |
| Income Before Tax | -272.71M | -276.48M | -297.59M | -311.55M | -333.39M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -272.71 | -276.48 | -297.59 | -311.55 | -333.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -272.71M | -276.48M | -297.59M | -311.55M | -333.39M |
| EBIT | -296.46M | -302.74M | -324.79M | -340.76M | -378.35M |
| EBITDA | -293.61M | -299.18M | -320.49M | -335.85M | -373.07M |
| EPS Basic | -1.57 | -1.61 | -1.75 | -1.95 | -2.23 |
| Normalized Basic EPS | -0.98 | -1.01 | -1.09 | -1.21 | -1.45 |
| EPS Diluted | -1.57 | -1.61 | -1.75 | -1.95 | -2.23 |
| Normalized Diluted EPS | -0.98 | -1.01 | -1.09 | -1.21 | -1.45 |
| Average Basic Shares Outstanding | 696.91M | 686.29M | 680.22M | 648.06M | 609.62M |
| Average Diluted Shares Outstanding | 696.91M | 686.29M | 680.22M | 648.06M | 609.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |